Wednesday, August 5 at 12-1pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

This webinar will examine the long-term safety profile of efanesoctocog alfa in hemophilia A, drawing upon evidence from clinical studies and emerging real-world experience. Expert faculty will review key safety and efficacy outcomes with long-term treatment experience, and practical considerations relevant to patient management. The session will also explore how real-world utilization and outcomes complement clinical trial findings to provide a more comprehensive understanding of the therapy's performance in routine care. Attendees will gain insights into the evolving evidence base supporting treatment decisions for patients with hemophilia A.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.